


## *Implementing Health Care Reform:*

*Moving into the Next  
Chapter of Quality,  
Performance  
Improvement and  
Appropriate  
Medication Use*




# PQA Thanks its Sponsors





# PQA Board of Directors



## ***Executive Committee:***

Judy Cahill, AMCP (Chair)  
Thomas Menighan, APhA, (Vice-Chair)  
Becky Snead, NASPA, (Treasurer)  
Steven Anderson, NACDS, (Secretary)  
Laura Cranston, PQA, Inc. (Exec. Director)

## ***Board Members:***

Woody Eisenberg, MD, Medco  
William Fleming, PharmD, Humana  
Karen Ignagni, AHIP  
Jeffrey Kelman, MD, CMS  
David Marshall, Teva USA  
Mark McClellan, MD, PhD,  
Brookings Institution  
Eleanor Perfetto, PhD, Pfizer  
Bruce Roberts, NCPA  
Lee Rucker, AARP  
Bruce Sherman, MD, Whirlpool  
Karen Weiss, Food & Drug Administration



# PQA Welcomes its New Members



• *American Drug Utilization & Review Society*

• *Endo Pharmaceuticals*

• *First DataBank*

• *IQware Marketing, LLC*

• *Takeda Pharmaceuticals*

• *University of Mississippi: Dr. Ben Banahan*

• *University of Pittsburgh Medical Center*



# PQA Releases Two RFPs for New Measure Testing/Validation



- One set of measures is focused on medication-therapy management (MTM) programs,
- The second set is more broadly applicable for evaluation of pharmacies and prescription drug plans and includes two new PDC measures, a cardiovascular measure, several respiratory measures and a safety measure.
- Separate requests for proposals (RFPs) are provided each measure set. Interested vendors may submit responses to one or both RFPs.

# PQA Phase II Demonstrations: Key Facts & Timelines



- Demo Projects are getting started now: June 2010
- Designed to be 24-month studies and integrate medical and pharmacy claims data
- Phase II Collaborative teams:
  - Team #1: Rite Aid Corporation, Highmark, CECity (as their HIT partner), University of Pittsburgh*
  - Team #2: SuperValu Corporation, Humana, University of Illinois*
  - Team #3: PharmMD, Healthspring, Emdeon and the University of Tennessee*



# Phase II: Primary Research Objectives



- Test the effectiveness of 1 or more pharmacist interventions to improve medication use by measuring PQA's 15 Quality Measures and Pharmacy Consumer Experience Survey
- Create/refine standardized pharmacy performance quality reports to determine the cost-effectiveness of interventions for pharmacy managers and payors
- Produce data to enable PQA to build the case for reimbursement of the most cost-effective medication quality improvement services



# Phase II: Secondary Objectives



- Test P4P or other financial incentives for pharmacist reimbursement; or develop specifications for P4P actuarial model
- Evaluate the impact of quality scores on health outcomes
- Measure any negative effects of providing intervention
- Evaluate the scalability of the use of quality measures in large settings (e.g., multi-site)




## *PQA Thanks its Generous Supporters:*

- *Pfizer, Inc*
- *The Community Pharmacy Foundation*
- *NACDS Foundation*
- *Merck*
- *Glaxo Smith Kline*





# PQA's 2010 Workgroup Infrastructure





# PQA's Communication & Education

## Workgroup: PQA Survey



Please take a moment to complete the brief PQA Survey found in your registration packets!

Return to Karen Peterson or Chelsea Renfrow in the **REGISTRATION AREA** before the end of the day!

